Current Report Filing (8-k)
02 July 2016 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 27, 2016
Proteostasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-37695
|
|
20-8436652
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
200 Technology Square, 4th Floor
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (617) 225-0096
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On June 27, 2016, Christopher K. Mirabelli, Ph.D. notified Proteostasis
Therapeutics, Inc. (the Company) of his resignation from the Companys board of directors (the Board) and from his position as chairman of the Board, effective as of June 30, 2016. Dr. Mirabellis decision
to resign from the Board was not the result of any disagreement with the Company.
In connection with Dr. Mirabellis
resignation, the Board has appointed M. James Barrett, Ph.D. to serve as chairman of the Board, effective as of June 30, 2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: July 1, 2016
|
|
|
|
Proteostasis Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Meenu Chhabra
|
|
|
|
|
|
|
Meenu Chhabra
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2024 to May 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Proteostasis Therapeutics Inc (NASDAQ): 0 recent articles
More Proteostasis Therapeutics, Inc. News Articles